alexa Vitamin D Supplementation Decreases TGF-β1 Bioavailability In PCOS: A Randomized Placebocontrolled Trial
ISSN: 2161-1017

Endocrinology & Metabolic Syndrome
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

2nd World Congress on Polycystic Ovarian Syndrome
October 05-07, 2016 Orlando, Florida, USA

Mohamad Irani
Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, USA
Posters & Accepted Abstracts: Endocrinol Metab Syndr
DOI: 10.4172/2161-1017.C1.015
Background: There is an abnormal increase in TGF-β1 bioavailability in women with polycystic ovary syndrome (PCOS), which might play a role in the pathophysiology of this syndrome. Vitamin D (VD) supplementation improves various clinical manifestations of PCOS and decreases TGF-β1 levels in several diseases including myelofibrosis. Aim: The objective of the study was to determine the effect of VD supplementation on TGF-β1 bioavailability in VD-deficient women with PCOS and assess whether changes in TGF- β1/soluble endoglin (sENG) levels correlate with an improvement in PCOS clinical manifestations. Method: Prospective, randomized, placebo-controlled trial was used. 68 VD-deficient women with PCOS who were not pregnant or taking any exogenous hormones were recruited between October 2013 and January 2015. Forty five women received 50000 IU of oral vitamin D3 and 23 women received oral placebo once weekly for eight weeks. Serum TGF-β1, sENG, lipid profile, testosterone, dehydroepiandrosterone sulfate, and insulin resistance were measured. The clinical parameters were evaluated before and two months after treatment. Results: The VD level significantly increased and normalized after VD supplementation (16.3±0.9 [SEM] to 43.2±2.4 ng/mL; P<.01), whereas it did not significantly change after placebo. After the VD supplementation, there was a significant decrease in the following: the interval between menstrual periods (80±9 to 60±6 d; P=.04), Ferriman-Gallwey score (9.8±1.5 to 8.1±1.5; P<.01), triglycerides (138±22 to 117±20 mg/dL; P=.03), and TGF-β1 to sENG ratio (6.7±0.4 to 5.9±0.4; P=.04). In addition, the TGF-β1 to sENG ratio was positively correlated with Δ triglycerides (r=0.59; P=.03). Conclusions: VD supplementation in VD-deficient women with PCOS significantly decreases the bioavailability of TGF-β1, which correlates with an improvement in some abnormal clinical parameters associated with PCOS. This is a novel mechanism that could explain the beneficial effects of VD supplementation in women with PCOS. These findings may support new treatment modalities for PCOS, such as the development of anti-TGF-β1 drugs.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version